Early L-T4 intervention improves fetal heart development in pregnant rats with subclinical hypothyroidism rats by activating BMP4/Smad4 signaling pathway

D Xue (✉ Xuedandan1@163.com)  
Sichuan University West China Hospital  https://orcid.org/0000-0002-0212-933X

JL Sun  
General Hospital of Northern Theater commond

J Yang  
The First Hospital of China Medical University

Research article

Keywords: Subclinical Hypothyroidism, Cardiac development, Pregnant rats, L-T4, BMP4/Smad4 signaling pathway

DOI: https://doi.org/10.21203/rs.3.rs-23072/v2

License: ☑️ ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** It is unclear whether the offspring of SCH pregnant rats still have abnormal cardiac development, and whether early intervention with L-T4 can improve the abnormality of these offspring. Therefore, the aim of this study was to investigate the effect of early L-T4 intervention on the heart development of offspring of SCH pregnant rats and its possible molecular mechanism.

**Methods:** Eighty female Wistar rats were randomly divided into Sham group (placebo control), SCH group, LT4-E10 group (L-T4 treatment started on the 10th day of gestation), and LT4-E13 group (L-T4 treatment started on the 13th day of gestation). Each group was further divided into E16, E18, P5 (postnatal day 5 rats), and P10 (postnatal day 10 rats) subgroups. The levels of serum TT4 and TSH, the ratio of heart weight to body weight of offspring rats, the expression of metabolic enzymes, and the histopathology of cardiomyocytes were determined. To elucidate the effects of L-T4 on cardiac development of offspring of SCH pregnant rats, the expression levels of GATA4, Nkx2-5 and proteins involved in BMP4/Smad4 signaling pathway were detected by immunohistochemistry, real time quantitative polymerase chain reaction and Western blotting to elucidate the molecular mechanism of L-T4 regulating the heart development of the offspring of SCH pregnant rats. **Results:** Compared with Sham group, serum TSH was significantly increased in SCH pregnant rats. Moreover, early L-T4 intervention significantly reduced the levels of serum TSH. Compared with the offspring in the SCH group, early L-T4 intervention significantly increased the heart weight, heart weight to body weight ratio, the activities of succinate dehydrogenase (SDH), Na⁺/K⁺-ATPase and Ca²⁺-ATPase, but reduced myocardial cell shrinkage and nuclear staining, hyperemia/congestion and vacuolar degeneration. In addition, early L-T4 intervention not only significantly increased the mRNA and protein expression of Gata4 and Nkx2-5, but also increased the protein expression involved in BMP4/Smad4 signal pathway in myocardium of the offspring of SCH pregnant rats.

**Conclusions:** Early L-T4 intervention can regulate the cardiac development of the offspring of SCH pregnant rats by activating BMP4/Smad4 signaling pathway and increasing the expression of Gata4 and Nkx2-5 proteins.

**Background**

Subclinical hypothyroidism (SCH) is one of the most common thyroid diseases during pregnancy, affecting 2–3% of the global population. SCH was defined as increased serum thyroid-stimulating hormone (TSH) during pregnancy, but the level of free thyroxine (FT4) is normal [1]. Pregnancy has a great influence on the thyroid function of pregnant women. During pregnancy, stimulation of TSH receptors by human chorionic gonadotropin (HCG) increases the demand for T4 and T3 by approximately 50%. At the same time, the volume of thyroid increases by 10–40%, and the demand for thyroxine and iodine also increases by 50%, which will inevitably lead to hypothyroidism in the third trimester of pregnancy. For patients diagnosed with SCH before pregnancy, the symptoms of thyroid hormone deficiency during pregnancy will be more pronounced [2]. It is known that poor control of SCH during
pregnancy is related to pregnancy complications and growth retardation of offspring. In addition, women with hypothyroidism women have an increased risk of hypertension and fetal death. These data indicate that there is a certain relationship between pregnant women with SCH and the risk of fetal disease[3].

Since the cardiovascular system is rich in TSH receptor, it is relatively sensitive to the change of TSH levels [4]. Previous studies have showed that TSH levels above 7.0 mIU/L led to abnormalities in lipid metabolism, oxidative stress and endothelial function, thereby increasing the risk of atherosclerosis and congestive heart failure. In addition, patients with SCH under 65 years of age were associated with increased risk of coronary heart disease, heart failure, and cerebrovascular diseases. Patients with TSH levels above 10 mIU/L have a higher risk of heart failure with lower ejection fraction compared to participants with normal thyroid function [5]. The left ventricular diastolic dysfunction caused by SCH may be related to endothelial dysfunction, arterial stiffness and inflammation [6]. Another clinical study indicated that SCH was associated with slower heart rate and shorter corrected QT (QTc), which can easily lead to cardiac systolic dysfunction [7]. Longer P-wave duration, longer PR interval and decreased voltage were observed in patients with SCH. In addition, age and gender were known to be closely related to the occurrence of SCH [8]. However, it is still unclear the effect of pregnant women with SCH on fetal heart development and its possible molecular mechanism.

The study found that administration of 150 µg/day of levothyroxine, a manufactured form of the thyroid hormone thyroxine (T4), at 13 weeks of gestation can lead to increased TSH or decreased FT4 [9]. It has been confirmed that the demand for exogenous L-T4 dose of most pregnant women increase from 25–30% during the first 4 to 6 weeks of pregnancy and gradually increased within 16 to 20 weeks of pregnancy, and then stabilize until delivery [10]. It was reported that compared with healthy people, the left ventricular systolic and diastolic function of SCH patients was slightly affected. Moreover, L-T4 treatment reversed the change of left ventricular systolic and diastolic function of SCH patients, but has no significant effect on systolic pressure [11]. A similar study also found that for children with hypothyroidism and ventricular diastolic dysfunction, L-T4 treatment can significantly improve left ventricular dysfunction [12]. However, the effects of L-T4 on the fetal heart development of pregnant women with SCH and its possible mechanism are still unknown. Therefore, the aim of this preclinical study was to investigate the effect of L-T4 treatment on the fetal heart development in SCH pregnant rats and to explore its possible molecular mechanism.

**Methods**

**Animals and groups**

Eighty female Wistar rats, aged 6–8 weeks and weighing 180–200 g, were purchased from the Benxi Changsheng Biotechnology Co., Ltd. The animals were kept in the Experimental Animal Department of the Northern Theater General Hospital. The ambient temperature was maintained at 21–22 °C with 50–60% relative humidity. All rats were maintained under a 12:12-h light/dark cycle, with access to food and water ad libitum. Eighty rats were randomly divided into Sham group (placebo control), SCH group, LT4-
E10 group (L-T4 treatment started on the 10th day of gestation), and LT4-E13 group (L-T4 treatment started on the 13th day of gestation). Each group was further divided into E16, E18, P5 (postnatal day 5 rats), and P10 (postnatal day 10 rats) subgroups. The animal experiment procedure was approved by the Animal Care and Use Committee of the Generalr Hospital of Northern Theater Command, which complied with the national guidelines on the protection and use of laboratory animals.

**Establishment of the SCH rat model**

Establishment of the SCH rat model refers to the previously literature [13]. The rats were injected with 3% pentobarbital sodium (0.1 mL/100 g) and underwent thyroidectomy, while Sham group rats underwent sham thyroid surgery. The rats were fed normally for 4 w after operation, then the blood was collected from the retroorbital venous plexus, and serum TSH and TT4 were detected. When serum TSH levels were higher than that in Sham group, the TT4 levels were lower than that in Sham group, confirming the successful establishment of the SCH rat model. Four weeks after surgery, rats in the SCH group were injected subcutaneously with L-thyroxine (L-T4, Sigma, USA) 1.0 µg/100 g/day on the neck. Sham group rats were injected subcutaneously with physiological saline (50 µL/100 g/day) on the neck. Calcium lactate (0.1% w/v) was added to the drinking water for all rats after surgery. Nine days later, all rats were mated with normal male rats (male: female = 1: 2). The pregnant rats were then kept in single cages until delivery. The day of vaginal plus was confirmed by microscopic observation and designated as E0. Serum and tissue samples were collected at E16, E18, P5 and P10. At the end of the experiment, all rats were anesthetized with pentobarbital (50 mg/kg, intraperitoneal) and euthanized by thoracotomy and hearts removal.

**Measurement of TT4 and TSH**

Blood samples obtained from the rats were immediately centrifuged at 13,000 g for 15 min and stored at -80°C for measurement of serum TT4 (#CEA452Ge, Youersheng, China) and TSH (#CEA463Ra, Youersheng, China) using a supersensitive chemiluminescence immunoassay.

**ATPase activity analysis**

The ATPase activity was detected using an ultramicro Ca^{2+}-ATPase kit and Na^{+}/K^{+}-ATPase kit (#A070, Nanjing Jiancheng Bioengineering Institute, China) according to the manufacturer's instructions. The succinate dehydrogenase (SDH) activity was measured by kit(A022, Nanjing Jiancheng Bioengineering Institute, China). Protein content
was measured with a Coomassie blue protein assay kit (#WLA004a, wanleibio, China). ATPase activity was expressed as mol Pi liberated per mg protein per hour (mol Pi/(mg prot·hr)).

RNA isolation and quantitative real-time PCR

RNA was extracted from heart tissues from each group using TRIzol (Life Tech). First strand of cDNA was synthesized using total RNA and RT-PCR was carried out by TaqMan expression assays, and β-actin (#WL01845, wanleibio, China) was used as a internal reference. The sequences for Nkx2-5, Gata4, BMP4, Smad4 and GAPDH were performed through the ABI PRISM system. Primer sequences are shown: Bmp4 F 5’-ATCGTTACC TCAAGGGAGTGGGA-3’; Bmp4 R 5’-ATCGTTACTCAAGGGAGTGGGA-3’; Samd4 F 5’-CGTTCACGAGGCATTTAC-3’; Samd4 R 5’-GGGAGGGAGTTGGACTG-3’; Nkx2-5 F 5’-TGGACAAAGCGGAGACAGAC-3’; Nkx2-5 R 5’-TCAGCGGGCGACAGGTA-3’; Gata4 F 5’-AAACGGAAGCCAAGAAT-3’; Gata4 R 5’-GCTGCTGTGCCCATAGA GTGAG-3’; β-actin F 5’-GGAGATTACTGCCCTGGACTAGC-3’; β-actin R 5’-GGGGGGGAGGCTGCTGCTGCTT. Reactions were performed in a total volume of 20 µL and gene expression was determined by SYBR Premix Ex Taq TM II (TaKaRa Biotechnology Co., Ltd.) in accordance with the manufacturer’s instructions. Reactions began with a 10 s hot activation of Taq polymerase at 95 °C, followed by 40–45 cycles of amplification in three steps (denaturation at 95 °C for 5 s, 30 s annealing at 60 °C and 30 s extension at 72 °C). The mRNA expression was measured as a ratio to β-actin.

Immunohistochemistry staining

Immunohistochemistry staining was performed to localize Nkx2-5 (1:500, #A12688, wanleibio, China), Gata4 (1:1000, #WL01293, wanleibio, China), BMP4 (1:500, #WL02806, wanleibio, China) and Smad4 (1:300, #WL02049, wanleibio, China). Heart tissues were routinely embedded in paraffin, and sectioned at a 3–5 µm thickness. All sections were dewaxed, and incubated with 0.3% H2O2 for 10 min. The antigen was repaired by heating 0.03M citrate buffer (pH6.0) for 40 min at 95 °C, and then incubated with 5% goat serum albumin for 20 min to block the non-specific binding sites. All sections were incubated with primary antibody overnight at 4 °C in a wet box and stained with sheep anti-rabbit IgG-HRP secondary antibodies (Abcam, UK). The sections were stained using 3,3-diaminobenzidine (DAB) (Sigma, USA) and counterstained with hematoxylin solution. Tissue sections without primary antibodies were the negative controls. Finally, samples were observed and photographed under a microscope.

Western blotting
Western blotting was performed as described previously [14]. Heart samples were lysed in complete RIPA buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP40, 0.1% sodium dodecyl sulfate, 1 mM phenylmethylsulfonyl fluoride and 1 × protease inhibitor cocktail [Roche]) and homogenized using a Sonic Dismembrator 100. The concentration of tissue protein was detected using a BCA protein concentration test kit (#WLA004, wanleibio, China), and equal amounts of soluble protein were separated on 10% polyacrylamide gels, transferred onto a nitrocellulose membrane, and followed by routine western blot analysis. Primary antibody: Nkx2-5 (1:500, #A12688, wanleibio, China), Gata4 (1:1000, #WL01293, wanleibio, China), BMP4 (1:500, #WL02806, wanleibio, China) and Smad4 (1:300, #WL02049, wanleibio, China). Proteins were visualized using a Clarity™ Western ECL Substrate (#WLA003; wanleibio, China) and a Tanon 5200 Full automatic chemiluminescence image analysis system (Tanon Science and Technology Co., Ltd., Shanghai, China).

Statistical analysis

Statistical analysis was performed using SPSS 20.0 statistical software (IBM Corp., Armonk, NY, USA). Variables are expressed as the means ± standard error of the mean (SEM). Data were analyzed using t-tests and one-way ANOVA. Statistical significance was reached at a two-sided p < 0.05.

Results

Effects of L-T4 on serum TSH and TT4 expression in the offspring of SCH pregnant rats

In order to evaluate the thyroid function of SCH pregnant rats, the expression levels of serum TT4 and TSH of all pregnant rats were measured. The serum TSH level in SCH group was significantly higher than that in the Sham group (Fig. 1A, p < 0.05). There was no significant difference in TT4 expression level between the two groups, confirming the successful establishment of the SCH rat model (Fig. 1B). Interestingly, in the LT4-E10 and LT4-E13 groups, L-T4 treatment significantly reduced serum TSH expression level in SCH pregnant rats (Fig. 1A, compared to SCH group, p < 0.05). Moreover, there was no significant difference in the TT4 expression level between SCH, LT4-E10 and LT4-E13 groups. The results indicated that L-T4 treatment would affect the serum TSH expression levels in SCH pregnant rats, but did not change the expression level of TT4.

L-T4 treatment promoted cardiac development in the offspring of SCH pregnant rats

To explore the effect of L-T4 on the heart development of the offspring of SCH pregnant rats, the heart weight and the ratio of heart weight to body (heart/body) weight were examined. The results showed that the heart weight and the heart/body weight of the offspring in the SCH group were significantly lower
than that in the Sham group. Furthermore, in the LT4-E10 and LT4-E13 groups, L-T4 treatment significantly increased the heart weight and heart/body weight of the offspring of SCH pregnant rats (Fig. 2, compared to SCH group, p < 0.05). The results suggested that early administration of L-T4 can promote the heart development of the offspring of SCH pregnant rats.

**L-T4 treatment improved the metabolic function of cardiomyocytes in the offspring of SCH pregnant rats**

To clarify the effects of L-T4 on the metabolic ability of cardiomyocytes of the offspring of SCH pregnant rats, the activities of SDH, Na+/K+-ATPase and Ca^{2+}-ATPase were detected. The results showed that compared to Sham group, the activities of SDH, Na+/K+-ATPase and Ca^{2+}-ATPase of the offspring were significantly decreased in the SCH group at E16, E18, P5 and P10. In the LT4-E10 and LT4-E13 groups, L-T4 treatment significantly increased the activities of SDH, Na+/K+-ATP and Ca^{2+}-ATP (Fig. 3, compared to SCH group, p < 0.05). The results suggested that L-T4 treatment regulated the cardiac development of the offspring of SCH pregnant rats by increasing the metabolic function of the cardiomyocytes.

**L-T4 treatment attenuated cardiac tissue injury of the offspring of SCH pregnant rats**

The results of histopathological staining showed that the cardiomyocytes of the offspring in the Sham group were orderly arranged, and the structure of cardiomyocytes was clear and intact (Fig. 4). However, the cardiomyocytes of the offspring in the SCH group showed wrinkled, hyperchromatic and loosely arranged structures, with obvious hyperemia, congestion and vacuolar degeneration cell shrinkage, hyperchromatic nuclei, local hyperemia/congestion and vacuolar degeneration. Moreover, in the LT4-E10 and LT4-E13 groups, the degree of cardiomyocyte degeneration, inter-tissue congestion and vacuolar degeneration gradually improved after L-T4 treatment. The results suggested that L-T4 treatment during pregnancy can improve the pathological changes of the heart tissue of the offspring of SCH pregnant rats.

**L-T4 promoted the expression of cardiac development proteins in the offspring of SCH pregnant rats**

Real-time quantitative PCR, immunohistochemistry and Western blotting were used to detect the expression of mRNAs and proteins related to cardiac development and differentiation of the offspring of SCH pregnant rats. The results showed that the expression levels of Nkx2-5 and Gata4 mRNA of the offspring in the SCH group was significantly lower than that in the Sham group. Furthermore, in the LT4-E10 and LT4-E13 groups, L-T4 treatment significantly increased the expression levels of Nkx2-5 and Gata4 mRNA in the myocardium of the offspring (Fig. 5A-B, compared to SCH group, p < 0.05). Western
blotting analysis further confirmed the results that the expression levels of Gata4 and Nkx2-5 protein in the myocardium of the offspring in the SCH group was significantly lower than that in the Sham group, while L-T4 treatment further significantly increased the expression levels of Gata4 and Nkx2-5 protein in the myocardium of the offspring in the LT4-E10 and LT4-E13 groups (Fig. 5C-D, compared to SCH group, p < 0.05). Similarly, the results of immunohistochemical staining showed that Gata4 and Nkx2-5 proteins were mainly expressed in the nucleus of heart cells. Compared to Sham group, the number of Gata4- and Nkx2-5-positive cells of the offspring in the SCH group were significantly reduced. Moreover, L-T4 treatment significantly increased the number of Gata4- and Nkx2-5-positive cells of the offspring in the LT4-E10 and LT4-E13 groups (Fig. 5E-F, compared to SCH group, p < 0.05). The results suggested that L-T4 treatment can regulate the cardiac development of the offspring of SCH pregnant rats by increasing the expression of Gata4 and Nkx2-5 proteins.

**L-T4 treatment increased the expression of BMP4/Smad4 proteins in the offspring of SCH pregnant rats**

Real-time quantitative PCR, immunohistochemistry and Western blotting were used to detect the BMP4 and Smad4 mRNA and protein levels of the offspring's myocardium in SCH pregnant rats. The results showed that the mRNA levels of BMP4 and Smad4 in myocardial tissues of the offspring in the SCH group were significantly lower than that in the Sham group. Furthermore, L-T4 treatment significantly increased the expression of BMP4 and Smad4 mRNA in myocardial tissues of the offspring in the LT4-E10 and LT4-E13 groups (Fig. 6A-B, compared to SCH group, p < 0.05). The results of Western blotting analysis showed that the levels of BMP4 and Smad4 proteins in myocardial tissues of the offspring in the SCH groups were significantly lower than that in the Sham group, while L-T4 treatment significantly increased the expression of BMP4 and Smad4 proteins in both LT4-E10 and LT4-E13 groups (Fig. 6C-D, p < 0.05). Immunohistochemical staining showed that BMP4 and Smad4 were mainly located in the cytoplasm and nucleus of myocardial cells. The number of BMP4- and Smad4-positive myocardial cells in the offspring in SCH group was significantly lower than that in the Sham group. Similarly, L-T4 treatment significantly increased the number of BMP4- and Smad4-positive myocardial cells in the LT4-E10 and LT4-E13 groups (Fig. 6E-F, compared to SCH group, p < 0.05). The results suggest that L-T4 regulates the cardiac development of the offspring in SCH pregnant rats by activating BMP4/Smad4 signal pathway.

**Discussion**

Some studies have shown that the offspring of SCH pregnant rats were often accompanied by neurodevelopmental abnormalities, and early intervention with L-T4 can alleviate the neurodevelopmental abnormalities. However, it is not clear whether the offspring of SCH pregnant rats have cardiac developmental abnormalities, and whether L-T4 early intervention can improve the abnormalities of the offspring in SCH pregnant rats. The results of this study revealed that L-T4 treatment significantly decreased the serum TSH expression level in SCH pregnant rats, increased the heart weight and
heart/body weight ratio of the offspring in SCH pregnant rats, improved the metabolic function of myocardial cells, and alleviated the pathological changes of myocardial tissues. In addition, L-T4 significantly increased the mRNA and proteins expression of Gata4, Nkx2-5, BMP4, and Smad4 of the offspring in SCH pregnant rats. The results suggest that L-T4 early intervention regulates the cardiac development of the offspring in SCH pregnant rats by activating BMP4/Smad4 signaling pathway, and then increasing the expression of Gata4 and Nkx2-5 proteins.

Some studies have showed that maternal plasma thyroid hormone levels affect fetal development. When pregnant women have hypothyroidism during pregnancy, abnormal thyroid hormone levels can severely affect the development of neuromotor, auditory, cardiovascular, skeletal and respiratory systems [15], and fetal thyroidectomy can reduce the protein contents of the fetal heart, lung, and skeletal muscles. Because thyroid hormones are essential for the maturation of cardiomyocytes and cardiovascular system, it can promote the transformation of fetal cardiomyocytes from proliferation to hypertrophy and differentiation during full-term and early pregnancy [16]. Slow fetal growth inhibits the proliferation and maturation rate of cardiomyocytes, which are affected by cardiomyocyte defects and metabolism. Since the thyroid function of pregnant women affects the growth and maturation of fetal organs, the birth weight of the baby can indirectly reflect the level of thyroid function of pregnant women [17]. Evidence indicated that when the concentration of fetal thyroid hormone is kept within a relatively narrow range, it will not affect the normal development of the heart [18]. In addition, some experimental data indicated a positive correlation between plasma T4 concentrations and fetal and/or neonatal body weight. Similarly, the concentration of T4 in umbilical cord blood is positively correlated with the birth weight and height of the baby, because thyroid hormones can provide nutrition and oxygen signals to the fetus in the uterus to regulate fetal growth [19]. Therefore, fetal thyroid hormone is essential for the increase of fetal weight and differentiation of specific cell types at the critical stage of development at the full term. The results of animal experiments further showed that SCH cause growth retardation of fetal rats in the uterus, and even led to abortion or premature delivery [13] and permanent neurological defects of the offspring [20, 21]. In this study, we found that L-T4 early intervention not only significantly decreased the serum TSH levels in the SCH pregnant rats, but also increased the heart weight and heart/body weight ratio of the offspring, improved the metabolic function of myocardial cells of the offspring, and alleviated the pathological changes of myocardial tissues of the offspring. It was reported that hypothyroidism during pregnancy impaired the normal cardiac function of the offspring rats. Furthermore, and thyroid hormone deficiency affect the expression profiles of myomiR network in the heart of fetal rats and the expression of downstream targeting genes, which in turn led to increased expression of b-MHC and related cardiac dysfunction in adulthood [22]. An infant with ectopic thyroid tissue was found to have sinus bradycardia associated with congenital hypothyroidism [23]. Another study found that SCH was associated with decreased cardiac output in patients with impaired vascular smooth muscle relaxation and reduced nitric oxide level. These changes were related to the decreased expression of sarcoplasmic reticulum Ca\(^{2+}\)-ATPase and the inhibition of expression of ATP enzyme phosphoprotein [24]. Low circulating levels of thyroid hormone inhibited the activity of sarcoplasmic reticulum calcium ATP enzyme, which controlled the contraction and relaxation cycle through ATPase, leading to myocardial stiffness and eventually left
ventricular diastolic dysfunction [25]. On the other hand, L-T4 treatment significantly improved low density lipoprotein, total cholesterol, hypertension, diastolic dysfunction and delayed arteriosclerosis in patients with SCH [26]. The results suggested that L-T4 treatment can improve the cardiac development of the offspring in SCH pregnant rats, which was related to increasing the heart weight, improving the metabolic function of the cardiomyocytes and alleviating the pathological changes of cardiomyocytes.

The heart is an organ derived from the mesoderm, and its formation is regulated by a variety of genes. During the early development of embryonic heart, a variety of genes such as bone morphogenetic proteins (BMPs), fibroblast growth factor and activin/nodule are involved in heart development and differentiation [27, 28]. BMP signaling cascade plays a central role in the induction of mesoderm and heart development. The BMPs secreted by cardiomyocytes provide an environment for the activation of the superjacent endocardium. The BMP ligand binds to type II receptor and then activates type I receptor to phosphorylate Smad1, Smad5 or Smad8 signal transduction pathway regulated by BMP receptor [29]. When BMP is released from the receptor complex, the phosphorylated R-Smad binds to the common Smad4 to form a trimeric complex composed of two R-Smad and Smad4, and then induces the transcription of downstream genes [30]. BMP4 knockout Fetal mice died within 9.5 days after birth, and most of them had little or no mesoderm differentiation [31]. BMP4 can induce the expression of Nkx2-5 and Gata4 in cardiac progenitor cells, which is necessary for cardiac development and differentiation [32]. Gata4 is one of the key transcription factors in fetal heart development. Abnormal expression of Gata4 can cause various fetal heart malformations, such as septal defect, tetralogy of Fallot, myocardial trabecular dysplasia, and valve malformation [33–35]. In this study, our results showed that the mRNA and protein expression levels of Gata4, Nkx2-5, BMP4, and Smad4 of the offspring were significantly decreased in SCH pregnant rats. Remarkably, L-T4 early intervention not only significantly increased the mRNA and protein levels of Gata4 and Nkx2-5, but also activated the BMP4/Smad4 signaling pathway in the myocardium of the offspring of SCH pregnant rats. It was reported that exposure of pregnant rats to di (2-ethylhexyl) phthalate caused cardiac malformation in the offspring, which may be related to the inhibition of cardiac Gata4/mef2c/ch expression by activating Peroxisome proliferator-activated receptor gamma (PPARγ) [36]. Similar to the results of this study, a study found that the potential toxicity of PM2.5 to fetal heart tissue was related to the down-regulation of transcriptional factors Gata4 and Nkx2-5, which were functionally associated with to embryonic heart development and abnormalities of fetal heart structure and function [37]. Similarly, exposure of pregnant rats to PM2.5 aggravated cardiovascular dysplasia caused by homocysteine in their offspring. [38]. These results indicated that early treatment of L-T4 can significantly improve the myocardial development of the offspring of SCH pregnant rats, which may be related to the activation of BMP4/Smad4 and the regulation of Gata4 and Nkx2-5 protein expression.

**Conclusion**

In conclusion, early administration of L-T4 can regulate the cardiac development of the offspring of SCH pregnant rats by activating BMP4/Smad4 signal pathway, and then increasing the expression of Gata4 and Nkx2-5.
Abbreviations
SCH: Subclinical hypothyroidism; PPARγ: Peroxisome proliferator-activated receptor gamma; LT4-E10 group: L-T4 treatment started on the 10th day of gestation; SDH: Succinate dehydrogenase; T4: Thyroid hormone thyroxine; TSH: Thyroid-stimulating hormone; BMPs: Bone morphogenetic proteins.

Declarations
Acknowledgments
Not applicable

Funding
The study was supported by the PLA foundation of Key issues of logistical support department of the Central Military Commission (BWS16J010). The funding sources had no involvement in study design; data collection, analysis and interpretation; or report writing.

Availability of data and materials
The datasets generated and analysed during the current study are not publicly available due the principle of confidentiality of funding but are available from the corresponding author on reasonable request.

Authors’ contributions
D Xue and J Yang designed experiments, and wrote the manuscript. JL Sun revised and polished the manuscript. D Xue completed animal experiment, pathological experiment, molecular biology experiment and protein experiment. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the Animal Care and Use Committee of the Northern Theater General Hospital.

Consent for publication
Not applicable
Competing interests

The authors declare that there are no conflicts of interest.

References

1. Wu T, Flowers JW, Tudiver F, Wilson JL, Punyasavatsut N: Subclinical thyroid disorders and cognitive performance among adolescents in the United States. BMC Pediatr 2006, 6:12.
2. Teng W, Shan Z, Patil-Sisodia K, Cooper DS: Hypothyroidism in pregnancy. Lancet Diabetes Endocrinol 2013, 1(3):228-237.
3. Chan S, Boelaert K: Optimal management of hypothyroidism, hypothyroxinaemia and euthyroid TPO antibody positivity preconception and in pregnancy. Clin Endocrinol (Oxf) 2015, 82(3):313-326.
4. Santos OC, Silva NA, Vaisman M, Turano MD, Dytz MG, Huber GA, Braulio VB, Teixeira PF: Evaluation of epicardial fat tissue thickness as a marker of cardiovascular risk in patients with subclinical hypothyroidism. J Endocrinol Invest 2015, 38(4):421-427.
5. Biondi B, Cappola AR, Cooper DS: Subclinical Hypothyroidism: A Review. JAMA 2019, 322(2):153-160.
6. Bielecka-Dabrowa A, Godoy B, Suzuki T, Banach M, von Haehling S: Subclinical hypothyroidism and the development of heart failure: an overview of risk and effects on cardiac function. Clin Res Cardiol 2019, 108(3):225-233.
7. Cappola AR, Desai AS, Medici M, Cooper LS, Egan D, Sopko G, Fishman GI, Goldman S, Cooper DS, Mora S et al: Thyroid and Cardiovascular Disease Research Agenda for Enhancing Knowledge, Prevention, and Treatment. Circulation 2019.
8. Tayal B, Graff C, Selmer C, Kragholm KH, Kihlstrom M, Nielsen JB, Olsen AS, Pietersen AH, Holst AG, Sogaard P et al: Thyroid dysfunction and electrocardiographic changes in subjects without arrhythmias: a cross-sectional study of primary healthcare subjects from Copenhagen. BMJ Open 2019, 9(6):e023854.
9. Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA, Larsen PR: Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. N Engl J Med 2004, 351(3):241-249.
10. Cerbone M, Capalbo D, Wasniewska M, Mattace Raso G, Alfano S, Meli R, De Luca F, Salerno M: Cardiovascular risk factors in children with long-standing untreated idiopathic subclinical hypothyroidism. J Clin Endocrinol Metab 2014, 99(8):2697-2703.
11. Nakova VV, Krstevska B, Kostova ES, Vaskova O, Ismail LG: The effect of levothyroxine treatment on left ventricular function in subclinical hypothyroidism. Arch Endocrinol Metab 2018, 62(4):392-398.
12. Arslan D, Buyukinan M, Uysal C, Deniz CD: Evaluation of cardiovascular risk by growth-differentiation factor-15 and tissue Doppler imaging in children with subclinical hypothyroidism. Endocrine 2019,
13. Shan L, Zhou Y, Peng S, Wang X, Shan Z, Teng W: Implantation failure in rats with subclinical hypothyroidism is associated with LIF/STAT3 signaling. *Endocr Connect* 2019, 8(6):718-727.

14. Ansari MY, Ahmad N, Haqqi TM: Butein Activates Autophagy Through AMPK/TSC2/ULK1/mTOR Pathway to Inhibit IL-6 Expression in IL-1beta Stimulated Human Chondrocytes. *Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology* 2018, 49(3):i.

15. Forhead AJ, Fowden AL: Thyroid hormones in fetal growth and prepartum maturation. *J Endocrinol* 2014, 221(3):R87-R103.

16. Chattergoon NN: Thyroid hormone signaling and consequences for cardiac development. *Journal of Endocrinology* 2019, 242(1):T145-T160.

17. Thornburg K, Jonker S, O'Tierney P, Chattergoon N, Louey S, Faber J, Giraud G: Regulation of the cardiomyocyte population in the developing heart. *Prog Biophys Mol Biol* 2011, 106(1):289-299.

18. Miller TA: Growth in Congenital Heart Disease: Outcome or Predictor? *J Am Heart Assoc* 2018, 7(17):e010262.

19. Ribeiro LGR, Silva JF, Ocarino NM, Souza CA, Melo EG, Serakesides R: Excess Maternal Thyroxine Alters the Proliferative Activity and Angiogenic Profile of Growth Cartilage of Rats at Birth and Weaning. *Cartilage* 2018, 9(1):89-103.

20. Zhang F, Chen J, Lin X, Peng S, Yu X, Shan Z, Teng W: Subclinical hypothyroidism in pregnant rats impaired learning and memory of their offspring by promoting the p75(NTR) signal pathway. *Endocr Connect* 2018, 7(5):688-697.

21. Ge JF, Xu YY, Qin G, Cheng JQ, Chen FH: Resveratrol Ameliorates the Anxiety- and Depression-Like Behavior of Subclinical Hypothyroidism Rat: Possible Involvement of the HPT Axis, HPA Axis, and Wnt/beta-Catenin Pathway. *Front Endocrinol (Lausanne)* 2016, 7:44.

22. Yousefzadeh N, Jeddi S, Ghiasi R, Alipour MR: Effect of fetal hypothyroidism on MyomiR network and its target gene expression profiles in heart of offspring rats. *Mol Cell Biochem* 2017, 436(1-2):179-187.

23. Nakanomori A, Nagano N, Seimiya A, Okahashi A, Morioka I: Fetal Sinus Bradycardia Is Associated with Congenital Hypothyroidism: An Infant with Ectopic Thyroid Tissue. *Tohoku J Exp Med* 2019, 248(4):307-311.

24. Udovic M, Pena RH, Patham B, Tabatabai L, Kansara A: Hypothyroidism and the Heart. *Methodist DeBakey Cardiovasc J* 2017, 13(2):55-59.

25. Rodondi N, Bauer DC, Cappola AR, Cornuz J, Robbins J, Fried LP, Ladenson PW, Vittinghoff E, Gottdiener JS, Newman AB: Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. *The Cardiovascular Health study. J Am Coll Cardiol* 2008, 52(14):1152-1159.

26. Peeters RP: Subclinical Hypothyroidism. *N Engl J Med* 2017, 376(26):2556-2565.
27. Liu W, Deng Z, Zeng Z, Fan J, Feng Y, Wang X, Cao D, Zhang B, Yang L, Liu B et al: Highly expressed BMP9/GDF2 in postnatal mouse liver and lungs may account for its pleiotropic effects on stem cell differentiation, angiogenesis, tumor growth and metabolism. Genes Dis 2020, 7(2):235-244.

28. Zhou C, Yan Q, Zou QY, Zhong XQ, Tyler CT, Magness RR, Bird IM, Zheng J: Sexual Dimorphisms of Preeclampsia-Dysregulated Transcriptomic Profiles and Cell Function in Fetal Endothelial Cells. Hypertension 2019, 74(1):154-163.

29. Chang H, Huylebroeck D, Verschueren K, Guo Q, Matzuk MM, Zwijsen A: Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic defects. Development 1999, 126(8):1631-1642.

30. Garside VC, Chang AC, Karsan A, Hoodless PA: Co-ordinating Notch, BMP, and TGF-β signaling during heart valve development. Cellular and Molecular Life Sciences 2012, 70(16):2899-2917.

31. Wang J, Greene SB, Martin JF: BMP signaling in congenital heart disease: new developments and future directions. Birth Defects Res A Clin Mol Teratol 2011, 91(6):441-448.

32. Takei S, Ichikawa H, Johkura K, Mogi A, No H, Yoshie S, Tomotsune D, Sasaki K: Bone morphogenetic protein-4 promotes induction of cardiomyocytes from human embryonic stem cells in serum-based embryoid body development. Am J Physiol Heart Circ Physiol 2009, 296(6):H1793-1803.

33. Kardon G, Ackerman KG, McCulley DJ, Shen Y, Wynn J, Shang L, Bogenschutz E, Sun X, Chung WK: Congenital diaphragmatic hemias: from genes to mechanisms to therapies. Dis Model Mech 2017, 10(8):955-970.

34. Yuan SM: Fetal Arrhythmias: Genetic Background and Clinical Implications. Pediatr Cardiol 2019, 40(2):247-256.

35. He A, Gu F, Hu Y, Ma Q, Ye LY, Akiyama JA, Visel A, Pennacchio LA, Pu WT: Dynamic GATA4 enhancers shape the chromatin landscape central to heart development and disease. Nat Commun 2014, 5:4907.

36. Tang C, Deng Y, Duan H, Zhang Y, Li Y, Qiu D, Zhou K, Hua Y, Wang C: The effect of maternal exposure to di-(2-ethylhexyl)-phthalate on fetal cardiac development in mice. J Appl Toxicol 2018, 38(6):834-842.

37. Carter DR, Buckle AD, Tanaka K, Perdomo J, Chong BH: Art27 interacts with GATA4, FOG2 and NKX2.5 and is a novel co-repressor of cardiac genes. PLoS One 2014, 9(4):e95253.

38. Chen H, Chen X, Hong X, Liu C, Huang H, Wang Q, Chen S, Chen H, Yang K, Sun Q: Maternal exposure to ambient PM2.5 exaggerates fetal cardiovascular maldevelopment induced by homocysteine in rats. Environ Toxicol 2017, 32(3):877-889.

Figures
Effects of L-T4 treatment on the expression levels of serum TSH and TT4 in the offspring of SCH pregnant rats. (A) TSH expression level of pregnant rats in the Sham, SCH, LT4-E10 (L-T4 treatment started on the 10th day of gestation), and LT4-E13 (L-T4 treatment started on the 13th day of gestation) groups. There were 20 rats in each group. (B) TT4 expression level of pregnant rats in each group. *p < 0.05 vs Sham group; #p < 0.05 vs SCH group.
Figure 2

L-T4 promotes cardiac development in the offspring of SCH pregnant rats. (A) Body weight of the offspring of SCH pregnant rats. (B) The ratio of heart weight to body weight (Heart/Body Weight) of the offspring of SCH pregnant rats. Results are expressed as the mean ± SEM (n=5 per group). *p < 0.05 vs Sham group; #p < 0.05 vs SCH group.
Figure 3

L-T4 treatment improved the metabolic function of cardiomyocytes in the offspring of SCH pregnant rats. (A) Na+/K+-ATPase activity (B) Ca2+-ATPase activity (C) SDH activity. All experiments were repeated at least three times. Data were expressed as the mean ± SEM (n = 5 per group). *p < 0.05 vs Sham group; #p < 0.05 vs SCH group.
Figure 4

L-T4 attenuated cardiac tissue injury of the offspring of SCH pregnant rats. Representative histopathological images of each group (HE staining, scale bar = 50 μm).
Figure 5

L-T4 treatment promoted the expression of cardiac development proteins in the offspring of SCH pregnant rats. (A-B) Expression levels of Gata4 and Nkx2-5 mRNA in the offspring of SCH pregnant rats; (C-D) Representative Western blot images and quantitative analysis of Gata4 and Nkx2-5 expression levels; (E-F) Representative immunohistochemical images of Gata4 and Nkx2-5 expression and quantitative analysis of Gata4- and Nkx2-5-positive cells in each group (Scale bar = 50 μm). All experiments were repeated at least three times. Data were expressed as the mean ± SEM (n = 5 per group). *p < 0.05 vs Sham group; #p < 0.05 vs SCH group.
Figure 6

L-T4 treatment increased the expression of BMP4/Smad4 protein in the offspring of SCH pregnant rats. 
(A-B) Expression level of BMP4 and Smad4 mRNA in the offspring of SCH pregnant rats; (C-D) 
Representative Western blot images and quantitative analysis of BMP4 and Smad4 intensity in each 
group; (E-F) Representative immunohistochemical images of BMP4 and Smad4 expression and 
quantitative analysis of BMP4- and Smad4- positive cells in each group (Scale bar = 50 μm). All 
experiments were repeated at least three times. Data were expressed as the mean ± SEM (n = 5 per group). 
*p < 0.05 vs Sham group; #p < 0.05 vs SCH group.